Viking Therapeutics Inc.
Rating
Updated: Aug 19, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investi...
Latest News
6 hours ago · proactiveinvestors.com
Viking Therapeutics shares surge over 27% on weight loss drug maintenance dataViking Therapeutics (NASDAQ:VKTX), the clinical-stage biopharmaceutical company, surged over 27% in Tuesday morning trade after reporting trial data showing its obesity drug VK2735 maintained most patients' initial weight loss with less frequent dosing. The drug, a dual agonist targeting the GLP-1 and GIP receptors involved in appetite regulation, demonstrated weight loss maintenance after patients switched to less frequent dosing.
7 hours ago · marketbeat.com
Viking Therapeutics' VK2735 Shows Strong Weight-Loss Retention With Monthly DosingViking Therapeutics NASDAQ: VKTX reported top-line results from a maintenance dosing study of VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity, showing that participants retained much of their initial weight loss after transitioning from weekly treatment to every-other-week or monthly dosing schedules.
7 hours ago · schaeffersresearch.com
Viking Therapeutics Stock Surges on Drug Trial SuccessViking Therapeutics Inc (NASDAQ:VKTX) is scaling the Nasdaq Composite (IXIC) this morning, up 28% at $38.63, at last check.
10 hours ago · reuters.com
Viking Therapeutics' obesity drug shows 22% weight loss in studyViking Therapeutics said on Tuesday its experimental GLP-1 obesity drug helped patients lose 22% of their body weight after 33 weeks of weekly treatment in a maintenance study.
5 days ago · fool.com
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.VK2735's dual formulation and rapid weight loss onset could be key differentiators provided the phase 3 trials are successful. Tolerability and trial design adjustments are crucial for oral VK2735's success.
5 days ago · zacks.com
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to NoteThe latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.52, representing a -1.44% change from its previous close.
7 days ago · benzinga.com
What's Going On With the Dip in Viking Therapeutics Stock?Viking Therapeutics Inc. (NASDAQ:VKTX) shares are dropping Tuesday amid a broader risk-off session, even though the stock's longer-term uptrend and its sector's strength both remain intact.
8 days ago · seekingalpha.com
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptViking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
11 days ago · zacks.com
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
12 days ago · zacks.com
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for InvestorsViking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VKTX